San Diego-based medical device company ResMed has announced the acquisition of mementor, a consumer software developer offering a digital solution for insomnia.
The financial terms of the transaction were not disclosed.
The acquisition of Leipzig, Germany-based mementor lays the foundation for ResMed to build its digital sleep medicine portfolio in Germany, the company said. The deal closed on August 1st.
Mementor will be integrated into ResMed in Germany as an independent business area and will serve as a platform for further developments in the field of digital health. The acquisition allows mementor to leverage ResMed Germany’s broader network to increase adoption of its digital health application somnio.
The business segment is managed jointly by mementor co-founder and CEO Dr. Noah Lorenz and Katherina Jekerle, who was previously Senior Marketing Director of ResMed Germany and a member of the German leadership team.
WHY THIS MATTERS
Mementor has developed the digital health application somnio, which focuses on improving sleep in patients diagnosed with insomnia. Somnio closes a care gap by offering an alternative to the predominant drug therapy.
According to ResMed, somnio complements its efforts to raise awareness of insomnia and sleep apnea and provides access to effective home treatments.
Somnio is available in Germany via an “app on prescription”.
According to ResMed, Somnio is Germany’s first and only permanently approved digital health application in the field of sleep medicine. It is therefore reimbursable in Germany.
According to ResMed, the clinical effectiveness of somnio was proven in two randomized controlled studies, which showed a sustained improvement in the sleep of users after two and 12 months.
THE BIGGER TREND
mementor was developed in Switzerland in 2014 by Dr. Noah Lorenz, Alexander Rötger, Jan Kühni and Daniel Rotzetter founded and develops and owns the digital solution for insomnia therapy somnio.
It is Germany’s first and only permanently approved digital health application (DiGA) in the field of sleep medicine and is also compliant with the data protection requirements of the European Union according to the General Data Protection Regulation.
In Germany, about 1 in 10 people are affected by clinically relevant insomnia, and almost 3 in 10 people by sleep apnea.
According to ResMed, only a small percentage of those affected currently receive the cognitive behavioral therapy for insomnia (CBT-I) recommended in the German S3 guideline.
ResMed offers out-of-hospital software programs to support people with sleep apnea, COPD and other chronic conditions.
In June, ResMed signed a definitive agreement to acquire Medifox Dan, a German out-of-hospital software company, from software investor Hg for US$1 billion (€950 million).
ON THE RECORD
Katrin Pucknat, President of ResMed Germany, said: “The founders have identified a large and neglected area of healthy sleep with the opportunity to help millions of people solve their chronic sleep problems with an easy-to-use digital solution for the home. We look forward to working with the mementor team to help even more people in Germany get good, healthy sleep.”
Email the author: SMorse@himss.org